Avacta Acquires Coris Bioconcept
With the acquisition, Avacta gains Coris’ product portfolio including diagnostic tests for respiratory, gastro-enteric, and blood-borne pathogens and for the detection of antibiotic resistance markers.
Read MorePosted by Melanie Hamilton-Basich | Jun 2, 2023 | Company News |
With the acquisition, Avacta gains Coris’ product portfolio including diagnostic tests for respiratory, gastro-enteric, and blood-borne pathogens and for the detection of antibiotic resistance markers.
Read MorePosted by Andy Lundin | Oct 27, 2022 | Covid 19, Research |
Bruker launched PhenoRisk PACS RuO, a research-use-only NMR test for molecular phenomics research on Long COVID patients’ blood samples.
Read MorePosted by Chris Wolski | Dec 9, 2021 | Diagnostic Technologies |
Industry experts predict a year of change and transformation ahead as the COVID-19 pandemic continues to influence the way clinical labs operate.
Read MorePosted by Melanie Hamilton-Basich | Apr 8, 2021 | Covid 19 |
Avacta has entered into a global distribution agreement with Abcam to sell the Group’s SARS-CoV-2 research ELISA Affimer reagents.
Read MorePosted by Melanie Hamilton-Basich | Jan 29, 2021 | Covid 19, Mass Spectrometry, Microbiology |
The collaboration is to evaluate the clinical utility of a high-throughput bead assisted mass spectrometry covid-19 test developed with Adeptrix.
Read More